Home – Chasing My Cure
David Fajgenbaum author of Chasing My Cure Order Now
Related Articles
Team hits milestone toward prion disease treatment — Harvard Gazette
Patient-scientist and husband are among the researchers who developed a promising gene-editing treatment for the rare, fatal condition.
Drugs Have Uses We Can’t Imagine. He’s Using A.I. to Find Them.
Scientists are using machine learning to find new treatments among thousands of old medicines.
Arrow Left
If you or a loved one have ASD, please subscribe to our newsletter for the latest updates on this insight. Click the video above to…
Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman’s Disease | NEJM
A patient with longstanding multicentric Castleman’s disease that had progressed after multiple therapies was entering hospice care. Inhibition of tumor necrosis factor will have led…
Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman’s Disease | NEJM
A patient with longstanding multicentric Castleman’s disease that had progressed after multiple therapies was entering hospice care. Inhibition of tumor necrosis factor will have led…
A Hero’s Journey: With Guests Ethan Gilsdorf, David Fajgenbaum & Kurt Gray
Framing the narrative of your life as an epic journey can give you control and meaning.
Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer – PubMed
Peritumoral injection of lidocaine before breast cancer surgery significantly increases DFS and OS. Altering events at the time of surgery can prevent metastases in early…
Show 1401: Are Miracle Cures Hiding in Plain Sight? Unlocking the Lifesaving Potential of Old Drugs
A physician who survived a close call with death has dedicated his life to unlocking the lifesaving potential of old drugs.
A Doctor Fights to Save His Own Life: The David Fajgenbaum Story. | BIO
David Fajgenbaum was in his third year of medical school when he was diagnosed with a rare and life-threatening disease that began shutting down his…